A Banner Year for Biosimilars: The 19 FDA Approvals From 2024

The Top 5 Most-Listened to Podcasts of 2024

December 29th 2024

By Skylar Jeremias

On this episode of Not So Different, we reflect on 2024 and this show in particular, taking audiences back through the most popular podcast episodes of the year.

The Top 5 Most-Read Policy Articles of 2024

December 28th 2024

By Skylar Jeremias

The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.

How Vertical Integration Drives Innovation and Access in Biosimilars

December 27th 2024

By Skylar Jeremias

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.

The Top 5 Most-Read Conference Articles of 2024

December 26th 2024

By Skylar Jeremias

The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including strategies for market sustainability, safety of switching to biosimilars, and substantial savings through high biosimilar adoption, while also addressing ongoing challenges.

Top 5 Most-Read Regulatory Articles of 2024

December 25th 2024

By Skylar Jeremias

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first interchangeability designations for biosimilars referencing ustekinumab, adalimumab, denosumab, and aflibercept, marking key regulatory milestones in improving patient access to cost-effective treatments.

Top 5 Most-Read Oncology Articles of 2024

December 24th 2024

By Skylar Jeremias

The top 5 oncology biosimilar articles in 2024 cover Duke's recommendations for cell and gene therapy biosimilars, FDA approval of Shanghai Henlius Biotech's trastuzumab biosimilar, Boehringer Ingelheim layoffs, the safety of rituximab biosimilar CT-P10, and more.

BioRationality: A Critical Analysis of Pfizer Views on Sustainability of Biosimilars

December 23rd 2024

By Sarfaraz K. Niazi, PhD

Top 5 Most-Read Legal Articles of 2024

December 23rd 2024

By Skylar Jeremias

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and addressing challenges like litigation, regulatory hurdles, and patent disputes that shape the competitive landscape of affordable biologics.

Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access

December 22nd 2024

By Skylar Jeremias

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.

The Top 5 Most-Read Gastroenterology Articles of 2024

December 21st 2024

By Skylar Jeremias

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the year, while FDA and European approvals for ustekinumab biosimilars are set to improve access and reduce costs for patients with Crohn disease and ulcerative colitis.